<DOC>
	<DOCNO>NCT00372320</DOCNO>
	<brief_summary>This study examine whether experimental drug AdhAQP1 increase salivary flow patient whose parotid gland expose therapeutic radiation treatment head neck cancer . Radiation may damage parotid gland ( salivary gland locate skin front ear ) , lead dry mouth , infection , excessive tooth decay , mouth sore , difficulty swallow pain . AdhAQP1 contain human aquaporin-1 gene , code protein work transport water across cell , virus normally cause cold human , modify render ineffective . In animal experiment , AdhAQP1 increase saliva production short time . Patients 18 year age old receive radiation treatment head neck cancer least 5 year enrol study , evidence recurrent tumor , dry mouth secrete abnormally low level saliva parotid gland may eligible study . Candidates screen medical history , physical examination , blood , urine saliva test , electrocardiogram ( EKG ) , chest x-ray , MRI exam , gallium scan ( nuclear medicine test look inflammation salivary gland ) , technetium pertechnetate scan ( nuclear medicine test examine salivary gland function ) , parotid sialogram ( x-ray parotid gland ) , PET CT scan look sign tumor skin biopsy collect skin cell use immunological test . Participants salt sugar solution infuse catheter ( plastic tube ) parotid gland . After 10 minute , solution drain mouth swallow . Saliva collect parotid gland 6 24 hour administration salt sugar solution . Ten 14 day later , patient admit NIH Clinical Center 4 day follow test procedure : - On first day , administration , catheter , study drug AdhAQP1 one parotid gland . - Monitoring next 3 day change patient ' ability produce saliva . This include medical examination several blood , urine saliva collection . - Technetium scan day 2 . - Gallium scan day 2 . Patients return NIH follow-up visit 1 , 2 , 4 , 6 week AdhAQP1 infusion 3 , 4 , 5 , 6 12 month medical examination blood , urine saliva collection . Gallium , technetium MRI scan repeat several follow-up visit , sialograms do 6 12 month . Chest x-ray EKG repeat 4 6 month .</brief_summary>
	<brief_title>Effect AdhAQP1 Salivary Flow Patients Treated With Radiation Head Neck Cancer</brief_title>
	<detailed_description>The treatment head neck cancer patient include ionize radiation ( IR ) . Salivary gland IR field suffer irreversible damage . There conventional treatment available correct condition . Our research group develop AdhAQP1 recombinant serotype 5 adenoviral ( rAd5 ) vector base hypothesis replication deficient rAd5 vector capable safely transfer human aquaporin-1 ( hAQP1 ) cDNA parotid gland adult patient IR-induced salivary hypofunction , result elevate salivary output , albeit transiently . Salivary gland proven valuable gene transfer target numerous pre-clinical animal model study . hAQP1 , archetypal water channel , plasma membrane protein facilitate water movement across lipid bilayers . Rat minipig study clearly show AdhAQP1 strategy restore salivary flow IR-damaged salivary gland effective , study rat , non-human primate minipigs show AdhAQP1 similar rAd5 vector without significant untoward effect salivary gland delivery . The purpose clinical protocol test safety AdhAQP1 , measure efficacy , adult patient establish IR-induced parotid gland hypofunction . The targeted tissue site AdhAQP1 vector propose study single parotid gland . In Phase 1 dose-escalation study , safety evaluate use conventional clinical immunological parameter . The primary outcome measure biological efficacy parotid gland salivary output .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . 18 year age old . 2 . Capable provide informed consent . 3 . History radiation therapy head neck cancer , receive &gt; 45Gy parotid gland ( ) due primary neck radiation . 4 . Abnormal parotid gland function target parotid gland judge absence unstimulated parotid salivary flow stimulate parotid salivary flow target parotid gland &lt; 0.2 mL/min/gland 2 % citrate stimulation . 5 . Abnormal ( 99m ) TcO4 scintiscan ( reduced absent uptake ( 99m ) TcO4 ) target parotid gland follow circumstance : A ( 99m ) TcO4 scintiscan performed use determine eligibility isotope available . If isotope available , inclusion criterion applicable . 6 . Abnormal sialogram ( alter ductal network sialectasis ) target parotid gland . 7 . No current evidence malignancy otolaryngology assessment , include clinical history , nasopharyngolaryngoscopy , negative CT PET scan ( e.g . reference 58 ) . 8 . Absence shed wild type adenovirus saliva sample collect targeted gland predose visit 1 . Specifically , aliquot predose visit 1 saliva sample target parotid gland use infect A549 cell test presence shed WT Ad virus . If infectious virus emerge subsequent 710 day followup period , participant longer eligible treatment withdrawn study . However , cytopathic effect observe 710 day period , participant may treat provided eligibility criterion meet . If stimulate saliva collect predose visit 1 , inclusion criterion applicable . 9 . Must diseasefree least 5 year , diseasefree interval calculate date last cancer treatment ( i.e. , date last radiation , chemotherapy surgery ) date predose visit 1 . 10 . Willingness practice require birth control method ( `` barrier '' contraception , i.e. , condom , diaphragm ) AdhAQP1 longer detectable serum saliva . Women bear child ( post menopausal due surgical intervention ) also require practice barrier birth control method AdhAQP1 longer detectable serum saliva . 11 . Able stay NIH hospital period time necessary complete onsite phase protocol . 12 . No history allergy medication agent use protocol . 13 . On stable dos medication ( great equal 2 month predose visit 1 ) underlie medical condition . EXCLUSION CRITERIA : 1 . Pregnant lactating woman . Women childbearing potential require negative serum pregnancy test predose visit 1 negative urine pregnancy test within 24 hour treatment . 2 . Any experimental therapy within 3 month plan AdhAQP1 administration ( Day 1 ) . 3 . Any active respiratory tract infection 3 week prior plan AdhAQP1 administration ( Day 1 ) . 4 . Active infection require use intravenous antibiotic resolve least 1 week plan AdhAQP1 administration ( Day 1 ) . 5 . Evidence active substance alcohol abuse history substance alcohol abuse within two year predose visit 1 . 6 . Uncontrolled ischemic heart disease : unstable angina , evidence active ischemic heart disease ECG , congestive heart failure ( left ventricular ejection fraction &lt; 45 % MUGA echo ) cardiomyopathy . 7 . Asthma chronic obstructive pulmonary disease require regular inhaled systemic corticosteroid . 8 . Individuals take prescription medication ( anticholinergic , antidepressant ) likely result salivary hypofunction . 9 . Individuals history autoimmune diseases affect salivary gland , include Sj ( SqrRoot ) ( Delta ) gren syndrome , lupus , scleroderma , type 1 diabetes , sarcoidosis , amyloidosis , chronic graft versus host disease . 10 . Use systemic immunosuppressive medication , e.g. , corticosteroid . Topical corticosteroid allow . 11 . History second malignancy , within past 3 year , exception adequately treat basal cell squamous cell carcinoma skin situ carcinoma cervix . 12 . Active hepatitis B , hepatitis C HIV infection test use blood collect predose visit 1 . 13 . WBC &lt; 3000/microL ANC &lt; 1500/microL Hgb &lt; 10.0 g/dL platelet &lt; 100,000/microL absolute lymphocyte count less equal 500/microL use blood collect predose visit 2 . 14 . ALT and/or AST &gt; 1.5 time upper limit normal ( ULN ) alkaline phosphatase &gt; 1.5 time ULN use blood collect predose visit 2 . 15 . Serum creatinine &gt; 2 mg/dL use blood collect predose visit 2 . 16 . Individuals active smoker . 17 . Individuals consume one alcoholic beverage/day . 18 . Individuals allergy iodine shellfish thus unable sialographic evaluation . 19 . Individuals whose targeted parotid duct clinically accessible screen sialography evaluation . 20 . Individuals sialography distal stenosis target parotid gland would impede vector delivery . 21 . Individuals likely would require use general anesthetic ultrasound guide core needle biopsy ( applicable participant dose cohort 25 ) . 22 . Significant concurrent recently diagnose ( &lt; 2 month Day 1 ) medical condition , opinion Medically Responsible Investigator , could affect participant 's ability tolerate complete study . 23 . Live vaccine within 4 week first infusion . 24 . Previous participation rAd5 vector gene transfer study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 7, 2017</verification_date>
	<keyword>Adenovirus</keyword>
	<keyword>Aquaporin-1</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Radiation-Induced Salivary Hypofunction</keyword>
	<keyword>Salivary Gland</keyword>
	<keyword>Xerostomia</keyword>
	<keyword>Salivary Dysfunction</keyword>
	<keyword>Hyposalivation</keyword>
	<keyword>Dry mouth</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>side effect radiation damage</keyword>
</DOC>